685885-75-0

Upstream product

• 132291-95-3 4-(methanesulfonyloxymethyl)tetrahydropyran 
• 109-04-6 2-bromo-pyridine 
• 475174-65-3 2-ethylpyrazolo[1,5-a]pyridine 
• 475174-67-5 N-amino-2-(1-butynyl)pyridinium mesitylenesulfonate 
• 73569-69-4 1-methylmethoxy-3,5-dimethoxybenzene 
• 26050-64-6 methyl 4-bromo-3,5-dimethoxybenzoate 
• 61367-62-2 (4-bromo-3,5-dimethoxyphenyl)methanol 
• 685886-50-4 7-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-2-ethyl-3-nitropyrazolo[1,5-a]pyridine 
• 685886-86-6 tert-butyl N-cyclopropylmethyl-N-(2-ethylpyrazolo[1,5-a]pyridin-3-yl)carbamate 
• 685886-79-7 tert-butyl N-(2-ethylpyrazolo[1,5-a]pyridin-3-yl)-carbamate 
• 685886-78-6 2-bromo-1,3-dimethoxy-5-(methoxymethyl)benzene 
• 685886-67-3 [2,6-dimethoxy-4-(methoxymethyl)phenyl]boronic acid 
• 685885-89-6 7-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-2-ethylpyrazolo[1,5-a]pyridine-3-amine 
• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 

Downstream Products

• 685886-34-4 E₂₅₀₈ Tosylate 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: Potent and orally active antagonists of corticotropin-releasing factor 1 receptor

Design, synthesis, and structure-activity relationships of a series of 3-dialkylamino-7-phenyl pyrazolo[1,5-a]pyridines (I) as selective antagonists of the corticotropin-releasing factor 1 (CRF1) receptor are described. The most prominent compound to emerge from this work, 46 (E2508), exhibits potent in vitro activity, excellent drug-like properties, and robust oral efficacy in animal models of stress-related disorders. It has advanced into clinical trials.

METHOD FOR PRODUCING PYRAZOLE FUSED RING DERIVATIVE

Disclosed is a commercially advantageous method for producing a pyrazole fused ring derivative (such as a 7-phenylpyrazolo[1,5-a]pyridine derivative). Specifically disclosed is a method for producing a compound (I) represented by the formula (I) below or a salt thereof, which comprises a step A wherein a hydroxy group in a compound (IV) represented by the formula (IV) below is converted into a methoxy group, thereby obtaining a compound (I) or a salt thereof:

7-phenylpyrazolopyridine compounds

A compound represented by the formula: [wherein R1 is methoxy, methylthio, ethyl, etc.; R5 and R6 are each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R40, R41 and R42 are C1-6 alkoxy while the remaining one is methoxymethyl, etc.], a salt thereof, or a hydrate of the foregoing. This compound has excellent antagonism against corticotropin-releasing factor receptor.